Lupin expands US portfolio with launch of Topiramate ER capsules across four strengthsLupin expands US portfolio with launch of Topiramate ER capsules across four strengths

Introduction

Leading pharmaceutical company launched Topiramate Extended-Release Capsules in the United States following FDA approval, indicated for treatment of seizures and prevention of migraines for specific age groups.

Also Read: IRFC inks MoU for Tuticorin port outer harbour development

Share price movement of Lupin

On February 5, 2026, Lupin Ltd opened at ₹2,201.35, up 0.30% from its previous close of ₹2,194.60. The stock touched a high of ₹2,243.90 (2.25%) and a low of ₹2,198.30 (0.17%). By 11:48 AM, it traded at ₹2,241.70, up 2.15%, with a market capitalisation of ₹1,02,438.50 crore.

Lupin Launches Topiramate Capsules US

Lupin Limited announced the launch of Topiramate Extended-Release Capsules in the United States on February 4, 2026. The launch follows U.S. FDA approval of its ANDA for 25 mg, 50 mg, 100 mg, and 200 mg.

The capsules are bioequivalent to Trokendi XR® of Supernus Pharmaceuticals. They are indicated for treatment of partial-onset seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and migraine prevention for eligible age groups.

Stock performance of Lupin for Period of 1 week, 6 months, and 1 year

Lupin Ltd delivered a 2.96% return over the past week, gained 14.4% over six months, and rose 0.46% over the past one year.

Also Read: GHV Infra Projects JV bags ₹62 Cr Assam riverbank protection order from ADB

Shareholding pattern of Lupin

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	46.90%	46.90%	46.90%
FII	21.50%	20.50%	21.30%
DII	26%	27%	25.60%
Public	6.00%	6.10%	6.30%

About Lupin

Lupin Ltd (NSE: LUPIN) is a global pharmaceutical company headquartered in Mumbai, operating 15 manufacturing sites and 7 research centers, with products in over 100 markets.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs